Business
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Resmetirom (MGL-3196, Rezdiffra) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH)
About this update from Galmed Pharmaceuticals Ltd.
[{"type":"text","content":"TEL AVIV, Israel, March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Resmetirom (MGL-3196, Rezdiffra) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis.","length":595,"tagName":"p"},{"type":"image","alt":"Galmed Pharmaceuticals Logo","displaySize":"","headline":null,"caption":"Galmed Pharmaceuticals Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rkpv_HpbOjVKPN_v6KG17Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e","width":400,"height":95}}},{"type":"text","content":"With this latest patent, Galmed is strengthening and extending Aramchol's patent protection through September 2039, securing long-term market exclusivity for its novel NASH therapy.","length":190,"tagName":"p"},{"type":"text","content":"This 15-year exclusivity runway is a significant intellectual property milestone for Galmed, positioning the Company to fully capitalize on Aramchol's commercial potential in the coming years.","length":196,"tagName":"p"},{"type":"text","content":"The new patent comes at a pivotal moment in the NASH/MASH field, as the industry shifts toward combination therapies to address this complex disease.","length":149,"tagName":"p"},{"type":"text","content":"NASH is a chronic liver condition characterized by multiple intertwined pathologies – excessive liver fat, metabolic dysfunction, and fibrosis. Recent regulatory developments underscore the need for multi-faceted treatment approaches: in March 2024, the FDA approved Rezdiffra (Resmetirom) as the first-ever drug for NASH patients with liver fibrosis, a milestone that validates the therapeutic potential in this space. However, experts widely agree that no single agent is likely to fully t...